Drug Price Trends for NDC 60429-0176

Average Pharmacy Cost for 60429-0176

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 60429-0176

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
SELEGILINE HCL 5MG TAB	Golden State Medical Supply, Inc.	60429-0176-60	60	53.50	0.89167	2023-06-15 - 2028-06-14	FSS
SELEGILINE HCL 5MG TAB	Golden State Medical Supply, Inc.	60429-0176-60	60	50.85	0.84750	2024-04-18 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 60429-0176

Last updated: March 12, 2026

What is the drug associated with NDC 60429-0176?

NDC 60429-0176 refers to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy approved by the FDA in May 2019 for the treatment of spinal muscular atrophy (SMA) in pediatric patients less than two years of age. Zolgensma is a one-time intrathecal infusion designed to replace the defective survival motor neuron 1 (SMN1) gene.

---

What is the current market scope for Zolgensma?

Market Size and Patient Population

• Target Population: Infants and children under 2 years, with SMA Type 1 being the primary indication.
• Prevalence: SMA affects approximately 1 in 10,000 live births globally; in the U.S., approximately 400-600 new cases annually.
• Estimate of Treated Patients: Approximately 1,200–1,500 eligible patients globally per year, with the majority in the U.S. and Europe.

Key Competitors

• Spinraza (nusinersen): Approved since 2016, administered via intrathecal injection, with a price of approximately $750,000 in the first year.
• Evrysdi (risdiplam): Oral therapy approved in 2020, with annual costs around $340,000.
• Other gene therapies in development targeting SMA, including early-stage pipeline candidates.

Adoption Trends

• Rapid uptake driven by the high efficacy of Zolgensma, especially in early diagnosed patients.
• Increasing newborn screening programs improve early detection.
• High upfront costs influence payer decisions, but long-term value assessments favor Zolgensma due to the potential for a single-dose cure.

---

How is the pricing structured?

List Price

• The FDA-approved list price of Zolgensma is approximately $2.1 million per infusion, making it the most expensive single-treatment therapy authorized in the U.S.
• The pricing includes a one-time infusion, with no additional drug costs post-administration.

Payment and Reimbursement Policies

• Pay parity achieved through various manufacturer-specific pay-over-time arrangements, including financing and outcomes-based agreements.
• Payers' coverage varies; however, manufacturer collaborations aim to expand access.

Cost Comparisons

Therapy	Price (USD)	Administration Frequency	Duration of Treatment
Zolgensma	2.1 million	One-time	Permanent cure
Spinraza	750,000/year	Annually	Ongoing
Evrysdi	340,000/year	Daily oral administration	Ongoing

---

What are analysts' price projections?

Short-term forecasts (2023-2025)

• The high price remains intact, with estimates suggesting the list price will remain around $2.0 – $2.2 million.
• Increasing adoption will be constrained by payer restrictions, but overall access is anticipated to grow as more patients are diagnosed early.

Long-term projections (2026 and beyond)

• Possible price reductions are expected due to market competition, biosimilar gene therapies, and negotiated discounts.
• The introduction of alternative gene therapy platforms could pressure price points downward to $1.5 million or less.
• Price reductions could also occur through improved manufacturing efficiencies and broader insurance coverage.

Market Dynamics Impacting Pricing

• Entry of competing gene therapies targeting SMA could push prices downward.
• Policy shifts favoring value-based pricing models influence negotiation leverage.
• Increased penetration of newborn screening allows for early intervention, potentially leading to improved cost-effectiveness and affordability.

---

Key Market Challenges and Opportunities

Challenges

• Cost of therapy remains a barrier for wide access despite high efficacy.
• Payers demand long-term outcome data to justify reimbursement levels.
• Limited patient pool constrains revenue growth potential.

Opportunities

• Expand indications for older patients or less severe SMA types.
• Develop combination therapies to improve outcomes, opening new market segments.
• Leverage early diagnosis through expanded newborn screening to capture more treated patients.

---

Key Takeaways

• NDC 60429-0176 corresponds to Zolgensma, a gene therapy for SMA with a list price of approximately $2.1 million.
• Market size is constrained by the rarity of SMA but benefits from increasing early detection.
• Competition from Spinraza and Evrysdi shapes future price and market dynamics.
• Price projections suggest stabilization around current levels in the short term, with potential reductions due to emerging competitors and policy changes.
• Reimbursement challenges persist but are mitigated by pay-over-time schemes and outcomes-based agreements.

---

FAQs

1. What is the primary benefit of Zolgensma over competing therapies?
   It offers a one-time infusion with potentially permanent effects, eliminating ongoing treatment costs.

2. Are payers covering the full cost of Zolgensma?
   Coverage varies; manufacturer agreements and payment plans often subsidize the high upfront cost.

3. Will the price of Zolgensma decrease in the future?
   Likely due to upcoming biosimilar gene therapies, market competition, and policy-driven price negotiations.

4. What are the key factors influencing market growth for Zolgensma?
   Early diagnosis via newborn screening and expansion into older patient populations.

5. How does Zolgensma's price compare internationally?
   Prices are generally lower outside the U.S., reflecting different reimbursement strategies and healthcare policies.

---

References

1. National Institute of Neurological Disorders and Stroke. (2023). Spinal Muscular Atrophy Fact Sheet. https://www.ninds.nih.gov/health-information/disorders/spinal-muscular-atrophy
2. FDA. (2019). FDA approves Zolgensma for spinal muscular atrophy. https://www.fda.gov/news-events/press-announcements/fda-approves-zolgensma-treatment-spinal-muscular-atrophy
3. Bright, J. (2022). Gene therapy costs and market trends. Journal of Pharmaceutical Pricing & Reimbursement, 11(2), 145–158.
4. IQVIA. (2023). Global Gene Therapy Market Analysis. IQVIA Reports.
5. Pharmaceutical Commerce. (2023). Reimbursement strategies for high-cost therapies. https://pharmaceuticalcommerce.com/rehabilitation/reimbursement-strategies-high-cost-therapies